Effect of leuprolide acetate on ovarian function after cyclophosphamide- doxorubicin-based chemotherapy in premenopausal patients with breast cancer: Results from a phase II randomized trial

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Song, Guiping ^a   Gao, Hui ^b   Yuan, Zhixiang ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b QINGDAO UNIVERSITY   (China)

^c Sichuan Academy of Chinese Medicine Sciences   (China)

Author keywords

Chemotherapy; Leuprolide acetate; Ovarian function

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; FOLLITROPIN; LEUPRORELIN; PACLITAXEL; TAMOXIFEN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY MENOPAUSE; ESTRADIOL BLOOD LEVEL; FATIGUE; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HOT FLUSH; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARIAN PRESERVATION; OVARY FUNCTION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UROGENITAL TRACT DISEASE; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; OVARY; PROSPECTIVE STUDY; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG EFFECTS;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEUPROLIDE; MIDDLE AGED; OVARY; PREMENOPAUSE; PROSPECTIVE STUDIES;

EID: 84880683574     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0667-8     Document Type: Article

References (44)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53(1):5-26.
2. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6- luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 1990;61(6):861-5.
3. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324-30. doi:10.1200/JCO.2007.14.2471.
4. Kreuser ED, Hetzel WD, Billia DO, Thiel E. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev. 1990;17(2-3):169-75. doi:0305-7372(90)90043-F.
5. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24(7):1045-51. doi:10.1200/JCO.2005. 03.3969.
6. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-29.
7. Del Mastro L, Venturini M, Sertoli M. Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO-MIG1 study. Breast Cancer Res Treat. 2003;82(Suppl 1):S9 (Abstr).
8. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8.
9. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997;43(2):183-90.
10. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 2008;26(5):753-8. doi:10.1200/JCO.2007.14.1655.
11. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917-31. doi:10.1200/JCO.2006.06.5888.
12. Lamar CA, DeCherney AH. Fertility preservation: state of the science and future research directions. Fertil Steril. 2009; 91(2):316-9. doi:10.1016/j.fertnstert.2008.08.133.
13. Porcu E, Venturoli S, Damiano G, Ciotti PM, Notarangelo L, Paradisi R, et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online. 2008;17(2):265-7.
14. Meirow D. Fertility preservation in cancer patients using stored ovarian tissue: clinical aspects. Curr Opin Endocrinol Diabetes Obes. 2008;15(6):536-47. doi:10.1097/MED.0b013e32831a44a8.
15. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormonereleasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995;52(2):365-72.
16. Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006;17(1):74-8. doi:10.1093/annonc/mdj029.
17. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat. 2008;110(3):411-6. doi:10.1007/s10549-007-9745-y.
18. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006;106(3):514-23. doi:10.1002/cncr.21646.
19. Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2007;12(9):1055-66. doi:10.1634/theoncologist.12-9-1055.
20. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122(3):803-11. doi:10.1007/s10549-010-0996-7.
21. Zhang J, Gao W, Wang P, Wu Z. Relationships among hope, coping style and social support for breast cancer patients. Chin Med J (Engl). 2010;123:2331-5.
22. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropinreleasing hormone agonists for prevention of chemotherapyinduced ovarian damage: prospective randomized study. Fertil Steril. 2009;91(3):694-7. doi:10.1016/j.fertnstert. 2007.12.044.
23. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334-41. doi:10.1200/JCO.2010.32.5704.
24. Brookmeyer R, Crowley J. Confidence interval for the median survival time. Biometrics. 1982;38:29-41.
25. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in women with Hodgkin's disease I. Hormone function. JAMA. 1979;242(17):1877-81.
26. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365-70.
27. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11(8):1620-6.
28. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. Long-term results of combined chemotherapy radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5(1):27-37.
29. Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H. Long-termgonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol. 1994;68(3):105-10.
30. Park HJ, Koo YA, Im YH, Yoon BK, Choi D. GnRH agonist therapy to protect ovarian function in young Korean breast cancer patients. J Korean Med Sci. 2010;25(1):110-6. doi:10.3346/jkms. 2010.25.1.110.
31. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229-39.
32. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044-54. doi:10.1634/theoncologist.12-9-1044.
33. Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest. 2007;63(2):102-6. doi:10.1159/000096062.
34. Ismail-Khan R, Minton S, Cox C, Sims I, Laceivic M, Gross-king M, et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy [abstract]. J Clin Oncol. 2008;26(155):524.
35. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269-76. doi:10.1001/jama. 2011.991.
36. Ozcelik B, Turkyilmaz C, Ozgun MT, Serin IS, Batukan C, Ozdamar S, et al. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil Steril. 2010;93(5):1609-14. doi:10.1016/j. fertnstert.2009.02.054.
37. Gucer F, Balkanli-Kaplan P, Doganay L, Yuce MA, Demiralay E, Sayin NC, et al. Effect of paclitaxel on primordial follicular reserve in mice. Fertil Steril. 2001;76(3):628-9.
38. Yucebilgin MS, Terek MC, Ozsaran A, Akercan F, Zekioglu O, Isik E, et al. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. Aust N Z J Obstet Gynaecol. 2004;44(1):6-9. doi:10.1111/j.1479-828X.2004.00143.x.
39. Mailhes JB, Carabatsos MJ, Young D, London SN, Bell M, Albertini DF. Taxol-induced meiotic maturation delay, spindle defects, and aneuploidy in mouse oocytes and zygotes. Mutat Res. 1999;423(1-2):79-90.
40. Matsuo G, Ushijima K, Shinagawa A, Takahashi S, Fujiyoshi N, Takemoto S, et al. GnRH agonist acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Kurume Med J. 2007;54(1-2):25-9.
41. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92(11):903-11.
42. Arriagada R, Le MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol. 2005;16(3):389-96. doi:10.1093/annonc/mdi085.
43. Rivkin SE, Green S, O'Sullivan J, Cruz AB, Abeloff MD, Jewell WR, et al. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996;14(1):46-51.
44. Gerber B, Dieterich M, Muller H, Reimer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res Treat. 2008;108(1):1-7. doi:10.1007/s10549-007-9572-1.